可解释的机器学习算法识别了乳腺癌治疗中的中介代谢特征和生物标志物
Ning Xie1, Dehua Liao2, Binliang Liu1
1Department of Breast Cancer Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
研究人员确定了两个关键代谢物FAPy-adenine和2-pyrocatechuic acid,作为预测治疗反应的潜在生物标志物,在接受inetetamab治疗的HER2-阳性乳腺癌 (BC) 患者中.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 生物标志物发现发现
背景情况:
- HER2阳性乳腺癌 (BC) 是积极的,并用inetetamab治疗.
- 目前还没有可靠的生物标志物可以预测BC患者的内提他马布疗效.
研究的目的:
- 通过代谢学和机器学习发现用于inetetamab治疗的新生物标志物.
- 为了确定可以预测HER2-阳性BC.治疗反应的代谢物.
主要方法:
- 分析了23个接受inetetamab治疗的BC患者的血样本 (响应者与非响应者).
- 利用超高性能液态染色学-四极飞行时间质谱仪进行代谢物分析.
- 应用统计分析和机器学习来识别差异性代谢物和响应性生物标志物.
主要成果:
- 检测到6889个独特的代谢物,在视网醇代谢,脂肪酸和类固醇激素生物合成途径中进行丰富.
- 确定了FAPy-adenine和2-pyrocatechuic酸作为关键代谢物,与inetetamab反应相关.
- 观察到无进展生存期 (PFS) 和这些代谢物的化之间存在负相关性.
结论:
- 作为预测性生物标志物,FAPy-adenine和2-Pyrocatechuic acid在BC中显示出对inetetamab治疗结果的前景.
- 这些代谢物可以帮助诊断BC,并发现针对性治疗的预后标记物.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
